Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms: Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients

Clinical Cancer Research

Volumn 9, Issue 14, 2003, Pages 5346-5357

  Junttila, Teemu T ^a,b   Laato, Matti ^c   Vahlberg, Tero ^b   Söderström, Karl Ove ^c   Visakorpi, Tapio ^d   Isola, Jorma ^d   Elenius, Klaus ^a,c  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERBB RECEPTOR; ISOPROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CELL MEMBRANE; CONTROLLED STUDY; EXON; GENE AMPLIFICATION; GENE STRUCTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERSTITIAL CYSTITIS; INTRON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; CYSTITIS, INTERSTITIAL; HUMANS; MICE; NIH 3T3 CELLS; PROGNOSIS; PROTEIN ISOFORMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 0242694432     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., Downward, J., Mayes, E. L. V., Whittle, N., Waterfield, M. D., and Seeburg, P. H. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (Lond.), 309: 418-425, 1984.
2. Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T., and Toyoshima, K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature (Lond.), 319: 230-234, 1986.
3. Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., and Aaronson, S. A. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA, 86: 9193-9197, 1989.
4. Plowman, G. D., Culouscou, J. M., Whitney, G. S., Green, J. M., Carlton, G. W., Foy, L., Neubauer, M. G., and Shoyab, M. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA, 90: 1746-1750, 1993.
5. Shawver, L. K., Slamon, D., and Ullrich, A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell, 1: 117-123, 2002.
6. Mendelsohn, J., and Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene, 19: 6550-6565, 2000.
7. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 344: 783-792, 2001.
8. Raghavan, D., Shipley, W. U., Garnick, M. B., Russell, P. J., and Richie, J. P. Biology and management of bladder cancer. N. Engl. J. Med., 322: 1129-1138, 1990.
9. Souhami, R., and Tobias, J. Cancer and Its Management, Ed. 3, p. 536. Oxford: Blackwell Science Ltd, 1998.
10. Neal, D. E., Marsh, C., Bennett, M. K., Abel, P. D., Hall, R. R., Sainsbury, J. R., and Harris, A. L. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet, 1: 366-368, 1985.
11. Lipponen, P., and Eskelinen, M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br. J. Cancer. 69: 1120-1125, 1994.
12. Sauter, G., Haley, J., Chew, K., Kerschmann, R., Moore, D., Carroll, P., Moch, H., Gudat, F., Mihatsch, M. J., and Waldman, F. Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int. J. Cancer, 57: 508-514, 1994.
13. Turkeri, L. N., Erton, M. L., Cevik, I., and Akdas, A. Impact of the expression of epidermal growth factor, transforming growth factor α, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology, 51: 645-649, 1998.
14. Chow, N. H., Liu, H. S., Yang, H. B., Chan, S. H., and Su, I. J. Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study. Virchows Arch., 430: 461-466, 1997.
15. McCann, A., Dervan, P. A., Johnston, P. A., Gullick, W. J., and Carney, D. N. c-erbB-2 oncoprotein expression in primary human tumors. Cancer (Phila.), 65: 88-92, 1990.
16. Zhau, H. E., Zhang, X., von Eschenbach, A. C., Scorsone, K., Babaian, R. J., Ro, J. Y., and Hung, M. C. Amplification and expression of the c-erb B-2/ neu proto-oncogene in human bladder cancer. Mol. Carcinog., 3: 254-257, 1990.
17. Coombs, L. M., Pigott, D. A., Sweeney, E., Proctor, A. J., Eydmann, M. E., Parkinson, C., and Knowles, M. A. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br. J. Cancer, 63: 601-608, 1991.
18. Sauter, G., Moch, H., Moore, D., Carroll, P., Kerschmann, R., Chew, K., Mihatsch, M. J., Gudat, F., and Waldman, F. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res., 53: 2199-2203, 1993.
19. Underwood, M., Bartlett, J., Reeves, J., Gardiner, D. S., Scott, R., and Cooke. T. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res., 55: 2422-2430, 1995.
20. Rajkumar, T., Stamp, G. W., Pandha, H. S., Waxman, J., and Gullick, W. J. Expression of the type 1 tyrosine kinase growth factor receptors EGF receptor, c-erbB2 and c-erbB3 in bladder cancer. J. Pathol., 179: 381-385, 1996.
21. Smith, K., Fennelly, J. A., Neal, D. E., Hall, R. R., and Harris, A. L. Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res., 49: 5810-5815, 1989.
22. Berger, M. S., Greenfield, C., Gullick, W. J., Haley, J., Downward, J., Neal, D. E., Harris, A. L., and Waterfield, M. D. Evaluation of epidermal growth factor receptors in bladder tumours. Br. J. Cancer, 56: 533-537, 1987.
23. Ohta, J. I., Miyoshi, Y., Uemura, H., Fujinami, K., Mikata, K., Hosaka, M., Tokita, Y., and Kubota, Y. Fluorescence in situ hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer. Clin. Cancer Res., 7: 2463-2467, 2001.
24. Miyamoto, H., Kubota, Y., Noguchi, S., Takase, K., Matsuzaki, J., Moriyama, M., Takebayashi, S., Kitamura, H., and Hosaka, M. C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology, 55: 679-683, 2000.
25. Messing, E. M. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res., 50: 2530-2537, 1990.
26. Messing, E. M., Hanson, P., Ulrich, P., and Erturk, E. Epidermal growth factor-interactions with normal and malignant urothelium: in vivo and in situ studies. J. Urol., 138: 1329-1335, 1987.
27. Chow, N. H., Chan, S. H., Tzai, T. S., Ho, C. L., and Liu, H. S. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin. Cancer Res., 7: 1957-1962, 2001.
28. Junttila, T. T., Sundvall, M., Määttä, J. A., and Elenius, K. ErbB4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc. Med., 10: 304-310, 2000.
29. Elenius, K., Choi, C. J., Paul, S., Santiestevan, E., Nishi, E., and Klagsbrun, M. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene, 18: 2607-2615, 1999.
30. Elenius, K., Corfas, G., Paul, S., Choi, C. J., Rio, C., Plowman, G. D., and Klagsbrun, M. A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J. Biol. Chem., 272: 26761-26768, 1997.
31. Kainulainen, V., Sundvall, M., Määttä, J. A., Santiestevan, E., Klagsbrun, M., and Elenius, K. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J. Biol. Chem., 275: 8641-8649, 2000.
32. Gilbertson, R. J., Bentley, L., Hernan, R., Junttila, T., Frank, A. J., Haapasalo, H., Connelly, M., Wetmore, C., Curran, T., Elenius, K., and Ellison, D. W. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin. Cancer Res., 8: 3054-3064, 2002.
33. Sriplakich, S., Jahnson, S., and Karlsson, M. G. Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer? BJU Int., 83: 498-503, 1999.
34. Jimenez, R. E., Hussain, M., Bianco, F. J., Jr., Vaishampayan, U., Tabazcka, P., Sakr, W. A., Pontes, J. E., Wood. D. P., Jr., and Grignon, D. J. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res., 7: 2440-2447, 2001.
35. Lonn, U., Lonn, S., Friberg, S., Nilsson, B., Silfversward, C., and Stenkvist, B. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin. Cancer Res., 1: 1189-1194, 1995.
36. Liukkonen, T., Rajala, P., Raitanen, M., Rintala, E., Kaasinen, E., and Lipponen, P. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/Tl) bladder cancer: a prospective comparative study. The Finnbladder Group. Eur. Urol., 36: 393-400, 1999.
37. Lipponen, P., Eskelinen, M., Syrjanen, S., Tervahauta, A., and Syrjanen, K. Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur. Urol, 20: 238-242, 1991.
38. Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J., and Press, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol., 20: 719-726, 2002.
39. Egeblad, M., and Jaattela, M. Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells. Int. J. Cancer, 86: 617-625, 2000.
40. Zhang, K., Sun, J., Liu, N., Wen, D., Chang, D., Thomason, A., and Yoshinaga, S. K. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem., 271: 3884-3890, 1996.
41. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry, 18: 5294-5299, 1979.
42. Aaltonen, V., Bostrom, P. J., Soderstrom, K. O., Hirvonen, O., Tuukkanen, J., Nurmi, M., Laato, M., and Peltonen, J. Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro. Am. J. Pathol., 154: 755-765, 1999.
43. Tanner, M., Jarvinen, P., and Isola, J. Amplification of HER-2/neu and topoisomerase IIα in primary and metastatic breast cancer. Cancer Res., 61: 5345-5348, 2001.
44. Gilbertson, R., Hernan, R., Pietsch, T., Pinto, L., Scotting, P., Allibone, R., Ellison, D., Perry, R., Pearson, A., and Lunec, J. Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma. Genes Chromosomes Cancer, 31: 288-294, 2001.
45. Beerli, R. R., Graus Porta, D., Woods Cook, K., Chen, X., Yarden, Y., and Hynes, N. E. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol. Cell. Biol., 15: 6496-6505, 1995.
46. Ni, C. Y., Murphy, M. P., Golde, T. E., and Carpenter, G. γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (Wash. DC), 294: 2179-2181, 2001.
47. Srinivasan, R., Gillett, C. E., Barnes, D. M., and Gullick, W. J. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res., 60: 1483-1487, 2000.
48. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177-182, 1987.
49. Yarden, Y., and Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol., 2: 127-137, 2001.
50. Arteaga, C. L. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist, 7: 31-39, 2002.
51. Paik, S., Bryant, J., Tan-Chiu, E., Romond, E., Hiller, W., Park, K., Brown, A., Yothers, G., Anderson, S., Smith, R., Wickerham, D. L., and Wolmark, N. Real-world performance of HER2 testing-ational Surgical Adjuvant Breast and Bowel Project experience. J. Natl. Cancer Inst., 94: 852-854, 2002.
52. Roche, P. C., Suman, V. J., Jenkins, R. B., Davidson, N. E., Martino, S., Kaufman, P. A., Addo, F. K., Murphy, B., Ingle, J. N., and Perez, E. A. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J. Natl. Cancer Inst., 94: 855-857, 2002.
53. Baselga, J. Clinical trials of Herceptin(R) (trastuzumab). Eur. J. Cancer, 37: 18-24, 2001.
54. Moscatello, D. K., Holgado-Madruga, M., Godwin, A. K., Ramirez, G., Gunn, G., Zoltick, P. W., Biegel, J. A., Hayes, R. L., and Wong, A. J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res., 55: 5536-5539, 1995.
55. Wong, A. J., Ruppert, J. M., Bigner, S. H., Grzeschik, C. H., Humphrey, P. A., Bigner, D. S., and Vogelstein, B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA, 89: 2965-2969, 1992.
56. Press, M. F., Hung, G., Godolphin, W., and Slamon, D. J. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res., 54: 2771-2777, 1994.
57. Revillion, F., Bonneterre, J., and Peyrat, J. P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer, 34: 791-808, 1998.